The taxpayers charge that the state Legislature spent $26 million in taxpayer dollars on outside counsel to represent it when ...

EMA validates Type II Variation marketing application for Enhertu as post-neoadjuvant treatment for patients with HER2 positive earlybreast cancer: Tokyo Saturday, February 21, 20 ...

The trial for one of three people who Las Vegas prosecutors say took part in a multi-state shooting spree, which involved the ...

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU ® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 ...

Europe ages faster, but experts say the real question isn't who's older — but which system is better equipped to handle it.

Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca's ...

Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes. DESTINY-Breast05 and ...

I’ve covered a few times how Destiny 2 is positively dumping loot on players now, something I suggested in the stingy Edge of Fate/Portal days, but things have escalated to a kind of wild degree. The ...

With Bungie’s back against the wall, I’m pleased to say that this shorter, medium-sized expansion is much, much better than Edge of Fate, and while it doesn’t necessarily shake up the Destiny formula ...

Covering the video games industry since 2017, with experience in news, articles, lists, and reviews (and I blame The Legend of Zelda: Majora's Mask for that). If you are a fan of RPGs and want a third ...

As Destiny 2 gets closer to its tenth anniversary, the shared world action-RPG is currently at something of a crossroads. Following the end of The Final Shape, many players struggled to keep up with ...